Invesco
KPTI icon

Invesco’s Karyopharm Therapeutics KPTI Stock Holding History

Invesco’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$882K Buy
90,304
+73,566
+440% +$638K ﹤0.01% 2986
2026
Q1 		$93.2K Buy
+16,738
New +$128K ﹤0.01% 3634
2024
Q4 		– Sell
-3,877
Closed -$48.3K – 3786
2024
Q3 		$48.3K Buy
3,877
+1,176
+44% +$14.6K ﹤0.01% 3690
2024
Q2 		$35.1K Buy
2,701
+836
+45% +$13.8K ﹤0.01% 3851
2024
Q1 		$42.2K Sell
1,865
-33
-2% -$579 ﹤0.01% 3814
2023
Q4 		$24.6K Sell
1,898
-2,356
-55% -$31.7K ﹤0.01% 3794
2023
Q3 		$85.5K Buy
4,254
+618
+17% +$13.9K ﹤0.01% 3741
2023
Q2 		$97.6K Buy
3,636
+754
+26% +$32.5K ﹤0.01% 3730
2023
Q1 		$168K Buy
2,882
+474
+20% +$23.4K ﹤0.01% 3649
2022
Q4 		$123K Buy
2,408
+81
+3% +$5.62K ﹤0.01% 3795
2022
Q3 		$191K Buy
2,327
+254
+12% +$19K ﹤0.01% 3695
2022
Q2 		$141K Sell
2,073
-30
-1% -$2.75K ﹤0.01% 3819
2022
Q1 		$232K Sell
2,103
-2
-0.1% -$249 ﹤0.01% 3737
2021
Q4 		$203K Sell
2,105
-172
-8% -$17.1K ﹤0.01% 3769
2021
Q3 		$199K Buy
2,277
+370
+19% +$38.4K ﹤0.01% 3808
2021
Q2 		$295K Buy
1,907
+695
+57% +$101K ﹤0.01% 3636
2021
Q1 		$191K Sell
1,212
-443
-27% -$93.3K ﹤0.01% 3684
2020
Q4 		$385K Buy
1,655
+676
+69% +$157K ﹤0.01% 3308
2020
Q3 		$215K Sell
979
-10
-1% -$2.45K ﹤0.01% 3439
2020
Q2 		$281K Sell
989
-4,614
-82% -$1.36M ﹤0.01% 3358
2020
Q1 		$1.61M Sell
5,603
-10,038
-64% -$2.77M ﹤0.01% 2510
2019
Q4 		$4.5M Sell
15,641
-2,983
-16% -$647K ﹤0.01% 2226
2019
Q3 		$2.69M Buy
+18,624
New +$2.53M ﹤0.01% 2478
2015
Q3 		– Sell
-13
Closed -$5K – 3893
2015
Q2 		$5K Buy
+13
New +$5.62K ﹤0.01% 4203

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Invesco's KPTI Position: Q2 2026 in Review

Invesco increased its Karyopharm Therapeutics (KPTI) stake by 440% in Q2 2026, buying an estimated $638K and bringing the position to 90,304 shares worth $882K. The position accounts for ﹤0.01% of the portfolio, ranked #2986.

Invesco first reported a position in KPTI in Q2 2015 and has held it in 24 quarters since. The position peaked at $4.5M in Q4 2019. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Invesco held 90,304 shares of Karyopharm Therapeutics worth $882K as of Q2 2026.
  • Invesco bought 73,566 Karyopharm Therapeutics shares in Q2 2026, an estimated $638K.
  • Karyopharm Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2986 holding.
  • Invesco first reported a position in Karyopharm Therapeutics in Q2 2015 and has held it in 24 quarters since.
  • Invesco's Karyopharm Therapeutics position peaked at $4.5M in Q4 2019.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.